APPLICATION OF NITRATE IN PREPARATION OF DRUG PREVENTING OR TREATING BONE METABOLIC DISEASES

Abstract

A drug preventing or treating bone metabolic diseases and containing a nitrate, and applications of a nitrate in the preparation of a drug preventing or treating bone metabolic diseases, and the preparation of drugs regulating bodily immune abnormalities and bone marrow mesenchymal stem cell abnormalities.

Claims

1-10. (canceled)

11. An application of nitrate in a preparation of a drug preventing or treating bone metabolic diseases.

12. The application according to claim 11, wherein the nitrate is used for preparing a drug preventing or treating abnormal bone density diseases.

13. The application according to claim 11, wherein the nitrate is used for preparing a drug preventing or treating osteoporosis.

14. The application according to claim 11, wherein the nitrate is selected from a group consisting of one or more of the followings: sodium nitrate, potassium nitrate, and calcium nitrate and ammonium nitrate.

15. The application according to claim 12, wherein the nitrate is selected from a group consisting of one or more of the followings: sodium nitrate, potassium nitrate, and calcium nitrate and ammonium nitrate.

16. The application according to claim 13, wherein the nitrate is selected from a group consisting of one or more of the followings: sodium nitrate, potassium nitrate, and calcium nitrate and ammonium nitrate.

17. The application according to claim 14, wherein, the nitrate is provided in the form of a food or an extract that is rich in nitrate.

18. The application according to claim 15, wherein, the nitrate is provided in the form of a food or an extract that is rich in nitrate.

19. The application according to claim 16, wherein, the nitrate is provided in the form of a food or an extract that is rich in nitrate.

20. The application according to claim 11, wherein, a daily dose of the nitrate is 0.1-0.5 mmol/Kg b.w.

21. The application according to claim 12, wherein, a daily dose of the nitrate is 0.1-0.5 mmol/Kg b.w.

22. A drug preventing or treating bone metabolic diseases comprising nitrate as an active ingredient.

23. The drug preventing or treating bone metabolic diseases according to claim 22, wherein dosage forms of the drug preventing or treating bone metabolic diseases are tablets, capsules, pills, injections, syrups, oral liquids, granules or patches.

24. An application of nitrate in preparing drug regulating system immune abnormalities or bone marrow mesenchymal stem cell abnormalities diseases.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The present application will be further described below with reference to the accompanying drawings and embodiments. In the drawings:

[0018] FIGS. 1A-1F are graphs illustrating the effects of nitrate on bone density and trabecular bone in ovariectomized rats.

[0019] FIGS. 2A and 2B are graphs illustrating the effects of nitrate on tibia weight and body weight in ovariectomized rats, respectively.

[0020] FIGS. 3A and 3B are graphs illustrating the difference of nitrate content and nitrite content in serum after drinking water containing nitrate for 3 months, respectively.

[0021] FIGS. 4A-4D are graphs illustrating the effects of nitrate on immune regulation in ovariectomized rats.

[0022] FIGS. 5A and 5B are graphs illustrating the results of the nitrate in the improvement of BMMSC defects in ovariectomized rats.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0023] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application will be further described in detail with reference to the accompanying drawings and embodiments.

[0024] 1. Establishment of Osteoporosis Model and Nitrate Administration

[0025] 12-week-old female SD rats were selected for the osteoporosis model and bilateral ovaries of them were removed. The experiment objects were divided into 3 groups: the sham operation group (Sham), the ovariectomized group (OVX) and the nitrate group (Nitrate), and there were 10 rats in each group. In the nitrate group, drinking water with sodium nitrate was given on the second day after ovariectomy (ovarianectomy) at a concentration of 2.5 mmol/L, and the daily intake of nitrate in each rat was about 0.5 mmol/Kg bw, the water with nitrate was given for 12 weeks, while normal drinking water was given in the other groups.

[0026] 2. Bone Density Detection

[0027] The rat tibia was completely separated, and all attached muscles and connective tissue were removed. It was wrapped with wet gauze soaked in physiological saline and stored at 20 C. The upper part of the tibia was scanned with a Skyscan 1162 Micro-CT. The scan thickness was 9 m. The bone density and trabecular structure were quantitatively analyzed using the attached software.

[0028] Referring to FIGS. 1A-1F, which are graphs illustrating the effects of nitrate on bone density and trabecular bone in ovariectomized rats. Wherein, FIG. 1A is a schematic diagram of an experimental process of the nitrate group, in which a 12-week-old SD rat undergoing an ovariectomy operation was given drinking water with sodium nitrate, and after 12 weeks, the animals were sacrificed to collect specimens. FIG. 1B shows the MicroCT of the upper tibia of the rat, which shows that the tibial bone mass of the ovariectomized group (OVX) was significantly lost and after giving the nitrate, the bone mass of the tibia lost in the ovariectomized rats was significantly relieved. FIGS. 1C-1F are graphs of bone density (BMD), bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N), respectively, of MicroCT quantitative analysis (*P<0.05) for each group. The results show that the above parameters of the ovariectomized group (OVX) decreased significantly, while the Nitrate group was able to partially recover the above indicators.

[0029] FIGS. 2A and 2B are graphs illustrating the effects of nitrate on tibia weight and body weight in ovariectomized rats, respectively, (*P<0.05). The results show that the drinking water with nitrate can relieve the decrease of tibia weight in ovariectomized rats and has no significant effect on the weight gain of ovariectomized rats.

[0030] 3. Measurement of Nitrate and Nitrite in Serum

[0031] (1) Preparation of the standard: the double dilution of the original standard was 200 M-3.125 M

[0032] (2) Determination of Nitrite Concentration:

[0033] 1) Adding 50 l reaction buffer to blank holes;

[0034] 2) Adding 50 l sample or standard to reaction buffer;

[0035] 3) Adding 50 l of reaction buffer to each hole in sequence;

[0036] 4) Adding 50 l of Griess Reagent I in each hole in sequence;

[0037] 5) Adding 50 l of Griess Reagent II to each hole and incubating at room temperature for 10 minutes;

[0038] 6) Reading the OD value at 540 nm with a microplate reader and the value at 690 nm is used as calibration.

[0039] (3) Determination of Nitrate Concentration:

[0040] 1) Adding 50 l reaction buffer to blank holes;

[0041] 2) Adding 50 l sample or standard to reaction buffer;

[0042] 3) Adding 25 l of nicotinamide adenine dinucleotide (NADH) to each hole in sequence;

[0043] 4) Adding 25 l of nitrate reductase to each hole in sequence;

[0044] 5) Adding 50 l of Griess Reagent I to each hole in sequence;

[0045] 6) Adding 50 l of Griess Reagent II to each hole in sequence and incubating at room temperature for 10 minutes;

[0046] 7) Reading the OD value at 540 nm with a microplate reader and the value at 690 nm is used as calibration.

[0047] Referring to FIGS. 3A and 3B, which are graphs (*p<0.05) illustrating the difference of nitrate content and nitrite content in serum after drinking water containing nitrate for 3 months, respectively. Wherein, the content of nitrate and the content of nitrite in serum were significantly increased by drinking water with nitrate.

[0048] 4. Detection of Immune Indicators

[0049] (1) The Detection of the Peripheral Blood Regulatory T Cell Ratio in the Rats

[0050] 1) Blood was collected from the abdominal aorta of the rats in each group and the serum was collected.

[0051] 2) 100 l 0.1% BSA is added for resuspending, and then Anti-CD4, Anti-CD25 are added for incubating on ice for 30 minutes while avoiding light.

[0052] 3) The obtained mixture is centrifuged at 1500 rpm for 10 minutes, and then the supernatant is removed and 0.1% BSA is added for resuspending.

[0053] 4) The membrane-permeation solution is added on 4 C., 10 minutes.

[0054] 5) The obtained mixture is centrifuged at 1500 rpm for 10 minutes, and then the supernatant is removed and 0.1% BSA is added for resuspending.

[0055] 6) Anti-Foxp3 is added for incubating on ice for 30 minutes while avoiding light.

[0056] 7) The obtained mixture is centrifuged, and then the supernatant is removed and 500 l 0.1% BSA is added for resuspending.

[0057] 8) Detect by the flow cytometry.

[0058] (2) Detection of TGF-1, IFN- and IL-17

[0059] 1) The serum is diluted for 10 times, and 0.1 ml of which is placed into the 96-well plate of the kit. At the same time, the standard in the kit is taken and diluted in proportion, and then placed into the 96-well plate and incubated at 37 C./at room temperature for 30 minutes/1 hour according to the instructions. The obtained object is washed with a buffer for 3 times and each time lasts for 3 minutes.

[0060] 2) 100 l enzyme-labeled antibody is added for incubating for 15 minutes/30 minutes at 37 C./at room temperature. The obtained object is washed for 3 times and each time lasts for 3 minutes.

[0061] 3) 100 l substrate solution is added and then incubated for 15 minutes at room temperature/37 C.

[0062] 4) 100 l stop solution is added to stop the reaction for 5 minutes.

[0063] 5) The readings of the enzyme labeled instrument at 450 nm is obtained.

[0064] FIGS. 4A-4D are graphs illustrating the effects of nitrate on immune regulation in ovariectomized rats (*P<0.05). FIG. 4A shows the proportion of regulatory T lymphocytes in peripheral blood CD4 positive cells obtained by flow cytometry analysis of rat peripheral blood from each group. As shown in the Figure, drinking water with nitrate can reduce the decline of the regulatory T lymphocytes (Treg) of the ovariectomized rat. FIGS. 4B-4D show the levels of TGF-1, IFN- and IL-17 in the serum of each group. The results show that drinking water with nitrate could alleviate the down-regulation of TGF-1 in ovariectomized rats and alleviate the up-regulation of IFN- and IL-17.

[0065] 5. Stem Cell Proliferation and Osteogenic Differentiation

[0066] (1) Culture of Rat BMMSC

[0067] After necropsy, the skin of the hind limbs was removed. After exposing the femur and tibia, the bone marrow was extracted with a 1 mL syringe to flush out from the stump. Cells were cultured in the -MEM complete medium (containing 10% of bovine serum), and subcultured after the cells were clonally grown until 80% of the fusion.

[0068] (2) CCK8 Method

[0069] 100 l of cell suspension was inoculated in the 96-well plate, and the plate was pre-cultured in the incubator for 24 hours (under the condition of 37 C., 5% CO.sub.2). Then the plate was incubated in an incubator for 72 hours. 100 l of culture medium was added to each well and 10 l of CCK-8 solution was added to each hole. After 2 hours, the absorbance at 450 nm was measured with an enzyme labeled instrument.

[0070] (3) Osteogenic Differentiation

[0071] Preparation of osteoinductive medium: adding 2 mmol/L glutamine, 100 U/ml penicillin and 100 g/ml streptomycin, 10 mM -glycerophosphate sodium, and 10 nM Dexamethasone and 50 mg/L vitamin C to 10% fetal bovine serum -MEM medium. The 3-4th generation cells were inoculated into a 6-well plate at a concentration of 210.sup.3/cm.sup.2, and after the cells were grown to 80% confluent, it was replaced with the osteoinductive medium, and the medium was changed every 2 days. The formation of calcium nodules was observed under light microscope. After 2 weeks of induction, alizarin red staining was performed.

[0072] 4) Alizarin Red Staining

[0073] 1) Removing the medium and washing it twice with PBS;

[0074] 2) Fixing it with 70% ethanol at 4 C. for 1 h;

[0075] 3) Washing it with double distilled water for 2 times;

[0076] 4) Staining it with 40 mM alizarin red solution (pH 4.2) at room temperature for 1-10 minutes and visually observing the coloration;

[0077] 5) Washing it with double distilled water for 5 times and gently blowing;

[0078] 6) Observing it under the microscope and collecting images.

[0079] Referring to FIGS. 5A and 5B, which are graphs illustrating the results of the nitrate in the improvement of BMMSC defects in ovariectomized rats (*P<0.05). FIG. 5A shows the OD450 value detected by CCK8 of the third generation cells which are obtained by primary culture of the BMMSC of the rats of each group according to the above method. The results show that the drinking water with nitrate significantly reduced the proliferation of the BMMSCs of ovariectomized rats. FIG. 5B shows the results of alizarin red staining and quantification after 21 days of osteogenesis induction of the BMMSC of rats in each group according to the above method. The results show that the drinking water with nitrate significantly enhanced osteogenic differentiation of the BMMSCs of ovariectomized rats.

[0080] 6. Statistical Method

[0081] SPSS 17.0 statistical software was used for statistical analysis. Multiple sets of measurement data were compared using ANOVA analysis. P<0.05 was statistically significant.

[0082] The present application has been described based on specific embodiments, but those skilled in the art should understand that various changes and equivalent substitutions can be made without departing from the scope of the present application. In addition, in order to adapt to the specific occasions or materials of the present application, the present application is subject to numerous modifications without departing from the scope of protection thereof. Therefore, the present application is not limited to the specific embodiments disclosed herein, but includes all embodiments that fall within the scope of the claims.